NASDAQ: ABCLAbcellera Biologics Inc Stock
$3.53+0.01 (+0.28%)
Updated Mar 19, 2026
ABCL Price
$3.53
Fair Value Price
N/A
Market Cap
$1.07B
52 Week Low
$1.89
52 Week High
$6.52
P/E
-7.2x
P/B
1.11x
P/S
13.6x
PEG
N/A
Dividend Yield
N/A
Revenue
$75.13M
Earnings
-$146.41M
Gross Margin
100%
Operating Margin
-236.39%
Profit Margin
-194.9%
Debt to Equity
0.4
Operating Cash Flow
-$131M
Beta
1.33
Next Earnings
May 7, 2026
Ex-Dividend
N/A
Next Dividend
N/A
ABCL Overview
AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in progress, or under contract with 36 partners. AbCellera Biologics Inc. has a research collaboration and license agreement with Eli Lilly and Company. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ABCL's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ABCL
Ranked#181 of 469
Ranked#181 of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $32.78 | A | |
| $15.47 | A | |
| $181.80 | A |
Be the first to know about important ABCL news, forecast changes, insider trades & much more!
ABCL News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ABCL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ABCL is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ABCL is good value based on its book value relative to its share price (1.11x), compared to the US Biotechnology industry average (4.68x)
P/B vs Industry Valuation
ABCL is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ABCL due diligence checks available for Premium users.
Valuation
ABCL fair value
Fair Value of ABCL stock based on Discounted Cash Flow (DCF)
Price
$3.53
Fair Value
-$0.86
Undervalued by
512.45%
ABCL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
ABCL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.2x
Industry
28.51x
Market
31.34x
ABCL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.11x
Industry
4.68x
ABCL is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ABCL's financial health
Profit margin
Revenue
$44.9M
Net Income
-$8.9M
Profit Margin
-19.9%
ABCL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
ABCL's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.4B
Liabilities
$390.0M
Debt to equity
0.4
ABCL's short-term assets ($728.23M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ABCL's short-term assets ($728.23M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ABCL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ABCL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$34.7M
Investing
$75.1M
Financing
$4.1M
ABCL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ABCL vs Biotech Stocks
Abcellera Biologics Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.